A federal court in New Jersey July 20 dismissed all claims in the patent litigation between Novartis Corp. and Teva Pharmaceuticals USA Inc. over Teva’s bid to copy Novartis’s brand-name blood pressure treatment Lotrel (amlodipine besylate/benazepril) (Novartis Corp. v. Teva Pharmaceuticals USA Inc.)
Chief Judge Garrett E. Brown Jr. of the U.S. District Court for the District of New Jersey entered the order dismissing all claims and counterclaims without prejudice.
In 2009, the New Jersey federal court dismissed similar disputes between Novartis and Par Pharmaceutical Co. (7 PLIR 201, 2/20/09), and between Novartis and Lupin ( ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.